March 23 (Reuters) - Pharmaust Ltd PAA.AX :* EPICHEM THROUGH UNIT ENTERED LICENSING AGREEMENT WITH ILLINOIS-BASED THERMAQUATICA* AGREEMENT TO DEVELOP AND PROMOTE DISRUPTIVE WASTE...
Feb 15 (Reuters) - Pharmaust Ltd PAA.AX :* UPDATE ON PHASE IIB CLINICAL TRIAL RECRUITMENT* RECRUITMENT FOR PHASE IIB CLINICAL TRIAL HAS COMMENCED
Dec 22 (Reuters) - Pharmaust Ltd PAA.AX :* RECEIVES ETHICS APPROVALS TO COMMENCE PHASE IIB DOG CANCER TRIAL
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Neutral | Neutral | Buy | Strong Buy | Sell |
| Technical Indicators | Sell | Sell | Buy | Strong Buy | Sell |
| Summary | Neutral | Neutral | Buy | Strong Buy | Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2.16 | 2.20 | 2.14 | -0.01 | -0.46% | 462.30K | ||||
| 6.66 | 6.70 | 6.66 | -0.04 | -0.60% | 12.60K | Sydney | |||
| 1.415 | 1.42 | 1.405 | +0.005 | +0.35% | 405.55K | Sydney | |||
| 16.44 | 16.97 | 16.40 | -0.52 | -3.07% | 176.02K | ||||
| 0.215 | 0.00 | 0.00 | 0.000 | 0.00% | 4.98M | Sydney | |||
| 15.90 | 16.06 | 15.81 | +0.24 | +1.56% | 370.77K | Sydney | |||
| 6.52 | 6.57 | 6.50 | +0.060 | +0.93% | 2.00M | ||||
| 9.46 | 9.52 | 9.36 | -0.06 | -0.63% | 55.90K | Sydney | |||
| 0.022 | 0.00 | 0.00 | 0.000 | 0.00% | 0.00 | Sydney | |||
| 26.06 | 26.06 | 25.61 | +0.640 | +2.52% | 2.99M | Sydney | |||
| 3.78 | 3.78 | 3.745 | +0.040 | +1.07% | 5.84M | Sydney | |||
| 25.92 | 26.10 | 25.84 | -0.020 | -0.08% | 1.17M | Sydney | |||
| 1.905 | 1.945 | 1.90 | -0.020 | -1.04% | 912.03K | Sydney | |||
| 1.07 | 1.08 | 1.07 | -0.005 | -0.47% | 1.87M | ||||
| 0.99 | 1.00 | 0.00 | 0.00 | 0.00% | 0.00 |
PharmAust Limited, a clinical-stage company, develops targeted cancer therapeutics for human and animal healthcare. The company develops drug discovery intellectual property for the treatment of various cancers in humans and animals. Its lead candidate is Monepantel, which are in Phase II clinical trials for the treatment of cancer. The company also provides highly specialized medicinal and synthetic chemistry services on a contract basis to clients to the drug discovery and pharmaceutical industries. The company has a research agreement with the Walter and Eliza Hall Institute to investigate the effects of monepantel (MPL) upon human T-lymphotrophic virus-1 (HTLV-1) infections in vitro. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.